Holen Sie sich die Stockscreener-App
75.80
0.08%
-0.06
Handel nachbörslich:
75.79
-0.010
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$75.86
Offen:
$75.5
24-Stunden-Volumen:
752.27K
Relative Volume:
0.47
Marktkapitalisierung:
$36.95B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
38.38
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
-6.79%
1M Leistung:
+2.10%
6M Leistung:
-0.37%
1J Leistung:
-19.94%
1-Tages-Spanne:
$75.26
$75.94
1-Wochen-Bereich:
$75.25
$80.59
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
75.80 | 36.95B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
482.22 | 170.78B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
152.14 | 43.28B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.76 | 37.85B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
219.85 | 32.03B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
Alcon slips as Q4 financial results miss on both lines - MSN
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update) - MSN
Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com
Sight Sciences awarded $55.4 million in patent case against Alcon By Investing.com - Investing.com Australia
Alcon’s $186 Million South Fort Worth Bet Aims To Turbocharge Jobs - Hoodline
Alcon Inc stock (CH0432492467): Is vision care growth strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon inks incentives deal for $186 million Fort Worth expansion - The Business Journals
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100 - GuruFocus
Alcon Inc stock (CH0432492467): Why does its eye care dominance matter more for U.S. investors now? - AD HOC NEWS
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential - Yahoo Finance
Alcon Inc. stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady growth? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for sustained U.S. investor - AD HOC NEWS
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - The Manila Times
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - GlobeNewswire Inc.
On the Record: Alcon invests $60M in Cabell County facility - MSN
Alcon Inc. (ALC) Stock Analysis: A 16.43% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady investor gains? - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Is vision care dominance strong enough to unlock steady growth for - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady upside? - AD HOC NEWS
Systane Augentropfen: Eye Relief Demand Surges Amid Screen Time Boom - AD HOC NEWS
Systane Augentropfen: Dry Eye Relief Gains Traction Amid Screen Time Surge - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady U.S. investor ret - AD HOC NEWS
Alcon Inc stock (CH0432492467): Why Google Discover changes matter more now - AD HOC NEWS
Sight Sciences wins $34M patent ruling against Alcon - MSN
Systane Augentropfen: Eye Health Demand Surges Amid Screen Time Boom - AD HOC NEWS
Optician OnlineWCO & Alcon release interactive DED toolOptician Online - Trucknet UK
Bernstein SocGen reiterates Alcon stock rating on dry eye outlook - Investing.com UK
Bernstein SocGen reiterates Alcon stock rating on dry eye outlook By Investing.com - Investing.com Australia
Alcon Inc. stock (CH0432492467): Why does its eye care dominance matter more for U.S. investors now? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care demand strong enough to sustain long-term growth? - AD HOC NEWS
Are Medical Stocks Lagging Alcon (ALC) This Year? - Yahoo Finance
Alcon Announces U.S. Launch of Clareon TruPlus IOLs - VisionMonday.com
Systane Augentropfen: Eye Health Boom Puts Alcon's Dry Eye Leader in Focus - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is vision care's steady growth strong enough to unlock new upside? - AD HOC NEWS
Analysis Recap: Will Alcon Inc benefit from rate cutsEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Alcon launches Clareon TruPlus monofocal and toric IOL - Eyes On Eyecare
Alcon Inc stock: What you need to know before investing now - AD HOC NEWS
Assessing Alcon (SWX:ALC) Valuation After Clareon TruPlus Lens Launch At ASCRS Meeting - Yahoo Finance
Is It Time To Reconsider Alcon (SWX:ALC) After Its 15.5% One Year Share Price Decline - Yahoo Finance
This mining merger gives Alcon holders 61% of the combined company - Stock Titan
Bridges Investment Fund's Alcon Inc(ALC) Holding History - GuruFocus
Alcon Inc (ALC) Trading 3.96% Higher on Apr 8 - GuruFocus
AB SUSTAINABLE INTERNATIONAL THEMATIC FUND INC's Alcon Inc(XSWX:ALC) Holding History - GuruFocus
Alcon Shares Rise After Introducing Clareon TruPlus at ASCRS - Bitget
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS - Yahoo Finance
Alcon Inc. stock: Why eye health leader stands out for investors now - AD HOC NEWS
U.S. Federal Trade Commission – Proposed Merger Between Alcon, Inc. And Lensar, Inc. Abandoned Following Competition Concerns - marketscreener.com
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.18%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):